Jefferies Cautious on Medivation (MDVN)

Jefferies analyst Biren Amin had a cautious note on Medivation (NASDAQ: MDVN) today, saying a prostate cancer survey suggested peak pre-chemo share may be approaching and the Xtandi consensus may be too aggressive.

Amin commented, "MDVN shares have been quite strong in recent months supported by strong Xtandi Q4 sales, positive PII TERRAIN data, and an active biotech M&A environment. We surveyed 46 physicians on current Xtandi use in addition to the impact from TERRAIN PII data reported in early '15. We conclude that while '15 Xtandi sales estimates are achievable, we feel '16 Xtandi consensus estimates may be somewhat aggressive."

The firm reiterated a Hold rating and price target of $136.00

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $133.94 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Genuine Parts (GPC) PT Raised to $180 at CFRA
• Roth/MKM Out Positive on Bio-Path Holdings (BPTH), PT $40